Report Overview

China Sanfilippo Syndrome (MPS-III) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Sanfilippo syndromeis a rare genetic metabolismdisorder. A change in a single gene makes a child's body unable to break down certain carbohydrates (sugars). This leads to serious problems in the brain and nervous system. MPS III is classified as a rare disease with global incidence reported to be between 0.28 and 4.1 cases per 100,000 births. Globally MPS IIIA is the most common subtype affecting around 1 in 100,000 births, closely followed by type B at 1 in 200,000.



Market Drivers

China is a growing market for Sanfilippo syndrome (MPS III) due to factors such as increase in global incidence rate (0.28 and 4.1 cases per 100,000 births). Other factors that are contributes to the growth of the market are awareness campaigns by various organizations, affordable reimbursement scenario for treatment, the growing necessity for advanced therapeuticsand improved R&D activities.

However, there are some restraining factors for the growth of Sanfilippo syndrome (MPS III) therapeutics market in China such as high cost of medicines, misdiagnosis of the disease and lack of innovative therapies.